Andrew J. Denisuik

Room 543-745 Bannatyne Avenue
Winnipeg, MB, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).

Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).

Journal: The Journal of antimicrobial chemotherapy
Published: August 28, 2025

Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23.

Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23.

Journal: The Journal of antimicrobial chemotherapy
Published: August 28, 2025

Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007-18).

Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing Escherichia coli clinical isolates (CANWARD, 2007-18).

Journal: JAC-antimicrobial resistance
Published: March 24, 2022

ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18.

ESBL-positive Escherichia coli and Klebsiella pneumoniae isolates from across Canada: CANWARD surveillance study, 2007-18.

Journal: The Journal of antimicrobial chemotherapy
Published: April 08, 2021

Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18.

Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing Escherichia coli collected from Canadian hospitals: CANWARD 2007-18.

Journal: The Journal of antimicrobial chemotherapy
Published: April 07, 2021

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

Journal: The Journal of antimicrobial chemotherapy
Published: September 11, 2019

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

Journal: The Journal of antimicrobial chemotherapy
Published: September 11, 2019

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

Journal: The Journal of antimicrobial chemotherapy
Published: September 11, 2019

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Journal: Antimicrobial agents and chemotherapy
Published: August 27, 2018

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Journal: The Journal of antimicrobial chemotherapy
Published: July 24, 2018

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Journal: Drugs
Published: May 12, 2018

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Journal: Drugs
Published: December 13, 2017
Showing 1-12 of 23

Last Updated: 09/26/2026